Skip to Main Content

Paper Details

Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
J Clin Invest
21
2020
AML, FLT3, FLT3 TKD, FLT3 mutations, FLT3-mutant AML cells, FLT3-mutant acute myeloid leukemia, FMS-like tyrosine kinase 3, NCGC1481, TKD, Tyrosine, Tyrosine kinase domain, tyrosine
Author NameAffiliation
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Fan JiangViva Biotech Ltd.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Craig J ThomasCenter for Cancer Research, National Cancer Institute (NCI)
  • 1 - 4

Datasets

Release 1.2